$AVRW New and Perfect Skincare Product, Seratopical Solutions' "Harmony Toner", is Now Available on the Seratopical Website!
Great video with Facial Plastic Surgeon Dr. Michael Persky
Link: https://seralabshealth.com/products/

$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

Formulation based on prior patents by NRx founder

Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration

Company expects Composition of Matter patent protection

Company previously executed joint development agreement with US manufacturer of insulin pumps

RADNOR, Pa., April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100. This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine. Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously. This patentable invention may enable the administration of ketamine in insulin pump-like devices in the clinic setting, eliminating the requirement for intravenous infusion personnel. NeuroRx, Inc. previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine.

With this proprietary formulation, developed with our partner Nephron Pharmaceuticals, a leading sterile products manufacturer, NRx is expected to generate one or more patents, such as composition of matter or formulation.

HTX-100 is expected to be marketed by HOPE Therapeutics, Inc., a wholly owned subsidiary of NRx.

"The current formulation of IV Ketamine was developed for battlefield use in the 1960s and has remained relatively static since then. With our new formulation, and Nephron's state of the art manufacturing expertise, we are pleased to be approaching the market with an improved formulation ready for use in modern medicine," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "Development of a pH-neutral, subcutaneous form of ketamine administration enables a significantly less complex route of administration in the outpatient setting. Moreover, advances in insulin pump technology create the potential to monitor the brain wave activity and other physiologic parameters associated with ketamine administration and modulate ketamine therapy based on the patient's individual physiologic response."

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRx Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.


https://c212.net/c/img/favicon.png?sn=CL87341&sd=2024-04-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-development-of-new-proprietary-formulation-of-htx-100-iv-ketamine-302116345.html

SOURCE NRx Pharmaceuticals, Inc.

$IVDN News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth

PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.

Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com

Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html

$IQST is heating up, and word is, $1 is within reach when they announce their latest acquisition.

https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html

$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-123000217.html

$GDHG News: Golden Heaven Group Holdings Ltd. Enters into a Collaboration Agreement with Nanping City Dacheng Culture Communication Co., Ltd.

NANPING, China, April 2, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, today announced that on March 29, 2024, it entered into a collaboration agreement (the "Agreement") with Nanping City Dacheng Culture Communication Co., Ltd. ("Dacheng Culture").

Under the Agreement, Golden Heaven has agreed to lease certain land and property to Dacheng Culture to host a range of activities, including wedding photography, family photography, marriage proposal planning, Hanfu (traditional Chinese clothing) photography, and various celebratory events. Dacheng Culture has agreed to compensate the Company with an aggregate lease payment of RMB6 million, payable quarterly, over the contract period, which extends from March 29, 2024 to March 28, 2025.

Mr. Jin Xu, the CEO and Chairman of the Company, commented, "As previously disclosed on March 19, 2024, we entered into a similar collaboration agreement with Zigong City Dragon Culture & Arts Co. Ltd. These collaboration agreements are designed to leverage our park locations and family-oriented attractions, enhance site utilization and strengthen bonds with our guests. The diverse activities that Dacheng Culture plans to introduce to our parks are expected to attract more guests, elevate the guest experience and add to our revenue. We are enthusiastic about embarking on this venture and future collaborations."

About Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.

Forward-Looking Statements

This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Golden Heaven Group Holdings Ltd.
Email: group@jsyoule.com

Ascent Investor Relations LLC
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

https://c212.net/c/img/favicon.png?sn=CN77335&sd=2024-04-02 View original content:https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-enters-into-a-collaboration-agreement-with-nanping-city-dacheng-culture-communication-co-ltd-302105015.html

SOURCE Golden Heaven Group Holdings Ltd.

Potential spike SODE: Annual report and current filing: 1) unrestricted shares a measly 31M only 2) gross profit 3) no change in OS for years 4) no convertible debt...entry pps IMO...spike from under a cent to $1 pps in 2021; spike to 10 cent pps in 2022
https://www.otcmarkets.com/stock/SODE/disclosure

$LQWC LifeQuest’s (OTC Markets: LQWC) Wholly Owned Subsidiary Receives an Order for a 30m3/Day (7,900 Gallons/Day) Sewage Wastewater Treatment Plant From a Hospital in India

https://www.otcmarkets.com/stock/LQWC/news/LifeQuests-Wholly-Owned-Subsidiary-Receives-an-Order-for-a-30m3Day-7900-GallonsDay-Sewage-Wastewater-Treatment-Plant-Fro?id=435813

$CBMJ Float In Tight Hands! Patriot.TV Network...Streaming Deals on the Way! Float only 8.5M! Insane trading under $1 here!

Details Below👇️👇️👇️

$EDXC's low price is chance for us, ain't gonna miss that.

$TMSH(.0003)~New JV, Revenue & Tiny A/S and O/S~DD

1) TMSH Pink Current

https://www.otcmarkets.com/stock/TMSH/overview

--------------------
2) TMSH~1.5 Billion A/S, 1.37 Billion O/S

Authorized Shares: 1,500,000,000
Outstanding Shares: 1,376,873,176
Restricted: 118,922,800
Unrestricted: 1,257,950,376
Held at DTC: 1,203,046,402

https://www.otcmarkets.com/stock/TMSH/security
------------------

3) The company generates revenue and gross profit

Most recent as of September 30, 2023
Revenue: 124, 329 dollars
Gross profit: 91,146 dollars
Total asset: 2,709,518 dollars
Total liabilities: 1,635,093 dollars

https://www.otcmarkets.com/otcapi/company/financial-report/386110/content
--------------

4) TMSH: "We invite prospective investors to delve into this transformative investment opportunity by navigating our digital domains:

www.transglobalassets.com,
www.betterhealthsciences.ca,
www.cannascribe.com,
www.synergyhealthservices.ca and
www.betterpets.ca

These platforms reveal the exciting potential within TMSH, providing a unique vantage point into a promising future.

https://finance.yahoo.com/news/transglobal-assets-inc-ventures-pet-164300459.html
----------------

5) Recent news: TransGlobal Assets Inc. Ventures into Pet Health Industry through Strategic Joint Venture
Press Release | 03/21/2024

CHEYENNE, Wyo., March 21, 2024 (GLOBE NEWSWIRE) -- TransGlobal Assets Inc. (OTC: TMSH) is excited to announce a significant milestone as its wholly owned subsidiary, Better Health Sciences Inc., has entered into a Joint Venture Agreement with Better Health Sciences For Pets Corp., otherwise known as the Better Pets brand.

TransGlobal Assets Inc. (OTC: TMSH)
E-Mail: info@TransGlobalAssets.net
Twitter: https://twitter.com/TMSH_OTC
Website: https://betterhealthsciences.ca/

https://www.otcmarkets.com/stock/TMSH/news/TransGlobal-Assets-Inc-Ventures-into-Pet-Health-Industry-through-Strategic-Joint-Venture?id=433992

-----------------

6) TMSH~Joint Venture companies two new products have been approved by Health Canada

Better Pets - Balm
Approved and Coming Soon

Topical Balm
Recommended Use:
Better Pets - Pet Balm, acts as a barrier and moisturizer to support skin health when applied to a pet’s paws, elbows and nose.
NN.I5Q4
Better Pets - Pet Gel
Approved and Coming Soon

Topical Gel
Recommended Use:
Better Pets - Pet Gel, helps to promote and maintain healthy skin.
NN.Y7J0

https://www.betterpets.ca/store
-----------


This is my DD . Please make your DD

$CBMJ Patriot.TV Launch Party Next Week = Loading_Zone_Now

🎉 It’s happening! The http://Patriot.TV Launch Party is here and you're invited!
🌟 Join us and an amazing lineup of speakers including Jason Lewis, Colonel John Mills, Roger Stone, and the esteemed Lt. Gen. Michael Flynn.
📆 Dates: March 29th and 30th
⏰ Times: Friday 7:30 pm-10 pm CT, Saturday 9 am-4 pm CT
Let's unite to celebrate patriotism, lively discussions, and a shared dedication to our nation's future. Share with your friends and let’s make it a weekend to remember! 🇺🇸 #PatriotTV #LaunchParty #CelebrateFreedom

🎉 It’s happening! The https://t.co/5RAXNKPHef Launch Party is here and you're invited! 🌟 Join us and an amazing lineup of speakers including Jason Lewis, Colonel John Mills, Roger Stone, and the esteemed Lt. Gen. Michael Flynn.
📆 Dates: March 29th and 30th
⏰ Times: Friday… pic.twitter.com/yf5s0awRnt

— PATRIOT.TV (@FreedomIsUpToUS) March 21, 2024

iQSTEL's Early Q1 Figures!
Have you seen the numbers? $IQST is smashing records with over $46M already in the bag for Q1. And with the roadmap laid out, the $1 billion goal isn't just a dream—it's the destination. Buckle up!

https://www.prnewswire.com/news-releases/iqst--iqstel-announces-record-breaking-revenue-and-gross-margin-reaching-46m-ytd-revenue-before-end-of-q1-302095888.html

$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales

Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities

The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number

Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security

RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" today initiated actions to combat short sellers in the Company's stock.

The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short" may be unable to exchange that position for a position in the new security.

The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.

"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.


View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html

SOURCE NRx Pharmaceuticals, Inc.

$NRXP: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

Company to receive first allocation of ketamine for sale by month end

Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies

NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply

Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval

RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.

(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com

In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.

"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html

SOURCE NRx Pharmaceuticals, Inc.

SONX... Here's what the excitement is about..... Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.

Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.

An archived recording will be available on the “Investors” section of the company’s website at: https://investor.sonendo.com. The webcasts will be available for replay for at least 90 days after the event.

The recorded, final version of the **CBS news covering IFUS tonight is out. It was recorded**. The Text version has a link the front page of the IFUS website that features the SGP+(tm) game changer cattle feed. The story is about IFUS SGP+(tm) cattle feed donation to the North Texas cattle owners to help save what is left of their cattle, and the fact that this new super low cost game changer cattle feed is a huge solution to climate change driven disasters like North Texas suffered last week, that destroyed 1.1 Million acres of grass and cattle industry assets.

https://www.wafb.com/2024/03/07/new-innovative-cattle-feed-being-donated-north-texas/

$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression

The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter

Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.

Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens

RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.


NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.

"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "

The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.

Top-line results are expected around the end of this quarter.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.


https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html

SOURCE NRx Pharmaceuticals, Inc.

Crypto rocketing. Gold surging.

Time to exercise caution in relation to blue chips.

Something is coming. Big money is talking.

Endex Corp. - $EDXC recently experienced a downturn due to a missed filing deadline. However, the exciting part is that once they resolve their paperwork issues, there's significant potential for a substantial upward surge. 🌕 This might just be the rebound opportunity we've all been anticipating, so it's crucial to stay alert. Conduct thorough due diligence, but my intuition suggests that this could be a golden chance for gains. 📈💰 Don't overlook this – it's shaping up to be a promising investment prospect! 🚀

AIRI >>>> Keep on your watch lists. Check out chart. HAWK

IGPK🚀 and APRU🚀 and LSEB🚀

$RENB GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb @ein_news

$IGPK doing well today.............

Z

$CYDVF is breaking out, close to doubling over the last 5 days on refinery speculation. Sounds like the Koch Technology refinery is viable which will make a big impact on the price of Clayton Valley projects. Along with Century Lithium, it should be worth looking at Spearmint Resources $SPMTF and Noram Lithium $NRVTF as they share the same deposit with Century. Both Spearmint and Noram are at or near bottom so lower risk that one might expect.

$CYIO People liking today's news https://finance.yahoo.com/news/cyios-corp-shareholder-carboncred-carbon-150000460.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

Thanks Zardiw... thinking IGPK is ready for a run.

$IGPK Chart from #DDAmanda - #1 Stock Screener :

#Scans are preset. Push a Button. Find Winners Early:



Z

IGPK is the stock to own... Up 28% almost 16 million traded.... PR.. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173920217

ALT waking up from its slumber

mb

I think $IFUS is going to be the darling of wallstreet pretty soon as revenue and profits explode going forward.
The math and savings for customers is a no brainer.

This DD is just the tip of the ice berg

UCAR GREAT NEWS.... https://www.stocktitan.net/news/UCAR/u-power-limited-enters-into-a-memorandum-of-understanding-with-9awsqnctdkw1.html

Sweet

How much money will ranchers save by using $IFUS sgp+ ?
Copilot:
Ranchers can save a substantial amount of money by using SGP+(TM). Let’s break it down:

Cost Savings on Transportation:
Impact Fusion International, $IFUS has successfully wrapped their SGP+TM bales, each weighing approximately 1400 lbs. This allows them to ship between 28-30 bales on a flatbed trailer, up to a total weight of 44,000 lbs. This weight limit is now the legal requirement for transporting material on a flatbed trailer.
Ranchers who use SGP+TM benefit from not needing a backhaul once the SGP+TM arrives at its destination. This eliminates additional transportation costs.
The cost savings can be as high as 75% compared to traditional methods.

Feed Efficiency and Cost Reduction:

One bale of SGP+TM feeds 600 head of cattle per day based on their test ranch in Jefferson, TX.
For example, a feedlot with 12,000 head of cattle would need to order a minimum of 5 flatbed trailers a week, each containing 22 tons of SGP+TM at $150/ton. This results in a monthly cost of $63,000 or $756,000 per annum.

These substantial cost savings are in addition to improvements in herd performance, reduced overall ration requirements, and a decrease in other high-priced supplements and medications for sick herds.

In summary, ranchers can significantly reduce their feed costs by incorporating SGP+TM into their livestock management practices. The combination of efficient transportation logistics and improved feed quality leads to substantial financial benefits for the industry.

BlockchainK2 Corp. ($BITK) with its 21,326,414 outstanding shares, is poised to capitalize on opportunities in the blockchain industry, reflected in its wide 52-week range of 0.35 - 0.07.

$IVDN has rising sales, new customers, new distributors, patent protection, no debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.

All of this has come together as a result of management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news:

World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640

LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html

Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html

Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html

Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html

Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html

Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html

$BNNHF Benjamin Hill Mining is a dynamic exploration company with a focus on the Alotta Exploration Project and Aion Mining Corp.’s Coal Project.
With a strong presence in the mining industry, we’re driven to uncover valuable resources in promising geological settings. Our commitment
to responsible mining practices and efficient resource utilization ensures a brighter future for all stakeholders.

INBS NEWS: Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
February 13 2024 - 08:08PM
Edgar (US Regulatory)

With $KRY at $0.06, investigate growth prospects. They are dedicated to improving mineral properties and taking environmental responsibility seriously, and they are well-positioned for success.

$AVRW, with its high value assets including 15 patents and the increasingly successful Seratopical Revolution skin care product line, is very undervalued at current trading levels. The details are all well covered in the recent feature article below. AVRW is now set up to have a record sales and revenue growth year in 2024 based on all the positive groundwork that was laid in the past months.

$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter

From this article:

– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.

– Company Currently Holds 15 Patents.

– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.

– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.

– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.

– Q3 Net Revenue Increased Sequentially from Q2 2023.

– Sales Expected to Increase Significantly During Q4 and Into 2024.

– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.

– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.

– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.

$AVRW, with its high value assets including 15 patents and the increasingly successful Seratopical Revolution skin care product line, is very undervalued at current trading levels. The details are all well covered in the recent feature article below. AVRW is now set up to have a record sales and revenue growth year in 2024 based on all the positive groundwork that was laid in the past months.

$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter

From this article:

– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.

– Company Currently Holds 15 Patents.

– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.

– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.

– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.

– Q3 Net Revenue Increased Sequentially from Q2 2023.

– Sales Expected to Increase Significantly During Q4 and Into 2024.

– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.

– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.

– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.

$LLLI for the Border Crisis: Lamperd Less Lethal Welcomes Intersec as an Authorized Distributor of its Advanced Security Solutions for Riot Control and Crisis Response Products in Mexico and Other Countries

SARNIA, ON / October 17, 2023/ Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, is pleased to announce the signing of an agreement with Intersec, (http://www.intersec.com.mx/). This new agreement shall be for sales and distribution of the full Lamperd product line and training services to law enforcement, military and other government authorized agencies in Mexico and other countries around the world.

Intersec is a well established Mexican company founded in 1974, dedicated to meeting the needs of the Defense, Public and Private Security market. During this period of more than forty-eight years, the marketing policy of quality products and good service allowed Intersec to consolidate, thus obtaining recognition both in Mexico and abroad as a serious and professional marketing company representing multiple top security industry manufacturers. Intersec has already listed Lamperd Less Lethal as one of its key product suppliers on its website and is now actively marketing the Lamperd product line, especially for specific situations where less lethal solutions are needed such as the Mexican-USA border.

One of the reasons that Intersec elected to carry the Lamperd line is that Lamperd Less Lethal can deliver completed orders on a very timely basis as we perform all manufacturing in-house at our fully equipped and well staffed plant in Ontario, Canada with no outsourcing needed. Lamperd also has established very dependable local sources for all raw materials needed. Therefore, Lamperd can offer superior order fulfillment, generally in a matter of weeks as opposed to many months or even over a year, as is the case with other suppliers at this time.

CEO Barry Lamperd stated, “We are very much looking forward to developing our new marketing relationship with Intersec which is a well positioned and well connected distribution company with many active customers in Mexico and other countries. There has never been a time when effective security solutions were needed more. The Lamperd line is ready to meet all of Intersec’s needs as it has been painstakingly developed and optimized for effectiveness and safety in every type of crisis situation. We will issue further updates as we progress.”

See the full Lamperd Less Lethal product line and training services available at http://www.lamperdlesslethal.com.

About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors.
For more information visit: http://www.lamperdlesslethal.com

This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public
the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli

$MGRX Is Launching “PRIME”, Powered By KYZATREX Capsules, For An FDA Approved ORAL #Testosterone Replacement Therapy (#TRT) Product!
Link: https://globenewswire.com/news-release/2023/12/13/2795461/0/en/MANGOCEUTICALS-TO-INTRODUCE-PRIME-POWERED-BY-KYZATREX-%ef%b8%8f-CIII-TESTOSTERONE-UNDECANOATE-CAPSULES-FOR-AN-FDA-APPROVED-ORAL-TESTOSTERONE-REPLACEMENT-THERAPY-TRT-PRODUCT.html

The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as ‘Prime’ by MangoRx

Dallas, Texas & Raleigh, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals ("Marius") to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, 'PRIME' by MangoRx.

PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.

TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body's natural diurnal rhythm allowing for peak performance early in the day.

Twice daily oral TRTs offer painless administration, promote steady absorption, lower SHGB levels, increase free T levels to give the body more usable testosterone, and work with the body's natural diurnal rhythm. Oral softgels are also convenient, mess-free, and discreet.

Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.”

PRIME by MangoRx will bring KYZATREX to patients spanning 48 states through the Company’s telemedicine platform, which is optimized to deliver a smooth medical prescription process, including blood work and synchronous telehealth visits with a fully licensed prescribing physician. Orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx’s URAC accredited mail order partner pharmacy directly to the patient’s doorstep.

Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with our established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. We are extremely fortunate to be working with Marius and to be one of only a few companies with access to this innovative product. With our established marketing and telemedicine infrastructure in place, we are ready to hit the ground running and take PRIME to patients in need across the country next month."

Testosterone deficiency affects approximately four in ten men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society.3,4 Between 10% and 40% of men worldwide suffer from low testosterone levels.5

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

About Marius Pharmaceuticals

Marius Pharmaceuticals strives to better the lives of patients by focusing on therapies designed for hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system. For more information, please visit www.mariuspharma.com.

About KYZATREX® (testosterone undecanoate)

KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) and indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in symptoms of low testosterone, including quality of life, energy/fatigue, erectile function, sexual intercourse, and mood. The most common side effect reported in ≥2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established.

$SNNAF is worth a look for a short term trade here. Just acquired 2 new uranium projects beside Cameco and Denison in the Athabasca Basin in Saskatchewan and is adding Uranium to their pool of lithium projects. This one is a short term play but should be fairly easy money over a few weeks. Lifewater promotion expected to start in February.

$MGRX MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11
https://finance.yahoo.com/news/mangorx-brand-products-featured-barstool-130000834.html

$MGRX

$MGRX

IGPK
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173645992

I always wondered if you still looked at iHub from the shadows …lol. Happy 2024 to you as well.

Happy 2024 to all. 🙏😘🤗🔥✅

It is going to be an amazing week for everyone and a unique point in our journey.

The big news about NXGB will be released early next week to update shareholders.

Top News: https://bit.ly/NXGB_NEWS

NxGen Brands, Inc. is a publicly-traded company under the symbol NXGB.

The company is building a profitable nutritional supplement company,

comprising several brands. www.nxgenbrands.com.

Welcome to CBDW, the place where excellence and innovation meet!

Join us on this exciting journey, shaping the future of customer engagement in the digital age.

As a publicly traded company under the stock symbol CBDW, CBDW.ai |

A Brand by 1606 Corp., is leading the way in AI-driven customer experiences.

Mission: to revolutionize the CBD industry with technology. empowering businesses big and

small.for growth and success. To learn more, visit the website: http://CBDW.ai